Global Parkinson’s Disease Drug Market Forecast 2018-2028

03 August 2018
Pharma

Parkinson’s drug treatments will reach $570bn in 2022 new study predicts
A new report by visiongain forecasts worldwide sales of drugs to treat Parkinson’s disease will reach $5.70bn in 2022. Visiongain is a business information company based in London, UK.

Visiongain forecasts the overall market for Parkinson’s disease (PD) therapies will grow steadily to 2028. Rising disease prevalence, due to ageing populations will stimulate the market. Advances in technology and development of new drug targeting will further augment the drug market for the treatment of Parkinson’s disease. The research and development (R&D) pipeline holds promise too, especially for disease-modifying agents.

Current treatment options offer symptomatic relief, with dopamine-regulating drugs dominating the market. Visiongain forecasts the emphasis on dopamine will gradually shift to the emergence of two new drug classes, which show potential of addressing neuroprotective and disease modifying paradigms.

The Parkinson’s disease market holds much potential. An increase in prevalence and an unprecedented elder population provides the market room to grow and a consistent consumer base. The advent of generic alternatives has brought with it the final years of the current generation of blockbuster Parkinson’s disease medications, as a reduction in healthcare spending in key markets continues to drive generic growth.

Ultimately, the current generation of Parkinson’s disease pharmaceuticals, designed to help relieve symptoms, is coming to an end. Within the next decade, the advent of disease modifying therapies will reshape the Parkinson’s disease industry. Overall the Parkinson’s disease market is expected to grow with a CAGR of 6.6% from 2018-2028.” - Pharmaceutical & medical device analyst at Visiongain.

Visiongain’s new report finds the Parkinson’s treatment market will change by 2028, with new mechanisms of drug action capturing sales. Also, biomarkers will help validate trials of neuroprotective agents and prove disease modification.

That study shows revenue forecasts to 2028 at overall world market, submarket, product and national level. It forecasts world sales for the following segments:

• Levodopa/ Carbidopa
• Dopamine Receptor Agonists
• MAO-inhibitors
• COMT-inhibitors
• Anticholinergics
• Other Therapeutic Options

That investigation also analyses leading companies there, including Astrazeneca, Merck &Co., Novartis AG, GlaxoSmith Kline, Roche, Pfizer, Abbvie, Biogen Inc., Acorda Therapeutics Inc.

The analysis discusses R&D and commercial progress, shows research interviews and predicts PD drug revenues to 2028 in leading national markets. That work analyses North America, South America, Europe, Asia Pacific and Rest of the World.

Parkinson’s Disease: World Drug Industry and Market 2018-2028 adds to visiongain’s portfolio of reports on healthcare industries. Together those studies assess commercial potentials of pharmaceuticals, diagnostics and medical devices.

Recent News

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever